Alessandra Armeli

Mrs. Alessandra Armeli

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LBLuana Vittoria Bauso
Luana Vittoria Bauso
VFValeria La Fauci
Valeria La Fauci
SMSerena Munaò
Serena Munaò
DBDesiree Bonfiglio
Desiree Bonfiglio
AAAlessandra Armeli
Alessandra Armeli
GCGiovanna Calabrese
Giovanna Calabrese
Cancer is one of the leading causes of morbidity and death worldwide, making it a serious global health concern. Chemotherapy, radiotherapy, and surgical treatment are the most used conventional therapeutic approaches, although they show several side effects that limit their effectiveness. For these reasons, the discovery of new effective alternative therapies still represents an enormous challenge for the treatment of tumour diseases. Recently, anticancer peptides (ACPs) have gained attention for cancer diagnosis and treatment. ACPs are small bioactive molecules which selectively induce cancer cell death through a variety of mechanisms such as apoptosis, membrane disruption, DNA damage, immunomodulation, as well as inhibition of angiogenesis, cell survival, and proliferation pathways. ACPs can also be employed for the targeted delivery of drugs into cancer cells. With over 1000 clinical trials using ACPs, their potential for application in cancer therapy seems promising. Peptides can also be utilized in conjunction with imaging agents and molecular imaging methods, such as MRI, PET, CT, and NIR, improving the detection and the classification of cancer, and monitoring the treatment response. In this review we will provide an overview of the biological activity of some natural and synthetic peptides for the treatment of the most common and malignant tumours affecting people around the world.

Verified
Journal Article
Open access
PDF file
SMSerena Munaò
Serena Munaò
AAAlessandra Armeli
Alessandra Armeli
DBDesiree Bonfiglio
Desiree Bonfiglio
AIAntonella Iaconis
Antonella Iaconis
GCGiovanna Calabrese
Giovanna Calabrese
The skeletal and immune systems are intricately linked, forming a dynamic interface that regulates both bone homeostasis and immune function. This bidirectional relationship, central to the field of osteoimmunology, highlights how bone and immune cells interact via shared progenitors and signaling pathways. Osteoclasts and osteoblasts not only coordinate bone remodeling but also influence hematopoietic and immune functions within the bone marrow microenvironment. The concept of the “bone immune system” underscores this crosstalk, particularly in pathological and regenerative contexts. Despite progress, contradictory findings complicate our understanding of cytokine activity. Pro-inflammatory mediators such as TNF-α and IL-17 are typically associated with bone loss, yet under certain conditions, they paradoxically promote repair by stimulating osteoblast differentiation. Conversely, anti-inflammatory cytokines like IL-10 and TGF-β are generally protective, but their effects vary depending on local context, sometimes even impairing regeneration. These inconsistencies highlight unresolved questions and gaps in mechanistic insight into immune–bone interactions. Bone tissue engineering (BTE) has advanced through biomimetic scaffolds, osteogenic cells, and bioactive molecules, offering hope for large defect repair. However, clinical translation remains limited, largely because immune modulation is not fully integrated into scaffold design. Current preclinical models often fail to capture the complexity of immune–skeletal interplay, reducing predictive value. Addressing these gaps requires improved models and systematic evaluation of immunoregulatory biomaterials, paving the way for more effective and personalized regenerative therapies.

8 September 2026 in Macromolecular Materials and Engineering
Verified
Journal Article
Open access
Luigi FabianoLuigi Fabiano
Luigi Fabiano
GCGiuseppe Cinà
Giuseppe Cinà
RSRosalinda Sciacca
Rosalinda Sciacca
AAAlessandra Armeli
Alessandra Armeli
Marina MassaroMarina Massaro
Marina Massaro
Serena RielaSerena Riela
Serena Riela
Halloysite nanotubes (HNTs) are investigated as functionally active nanofillers for tuning PEDOT:PSS thin films. HNTs from Dragon Mine (DG, USA) and Matauri Bay (NZ, New Zealand), characterized by different aspect ratios and surface chemical characteristics, are incorporated at 1.0–7.5 wt.% without secondary dopants to highlight specific HNT‐related interfacial effects. A non‐monotonic dependence of local conductance on DG content is observed, with a maximum at low loading (2.5 wt.%). This trend reflects the balance between enhanced connectivity of PEDOT‐rich domains at low concentrations and disruption of conductive pathways due to nanotube aggregation at higher loadings. It is suggested that DG acts as an active modulator, promoting polymer chain reorganization and enabling a denser hopping network, thereby enhancing local electrical response and mechanical stiffness. In contrast, NZ behaves as a passive filler, preserving the intrinsic ion‐storage capability of PEDOT:PSS without improving charge transport, highlighting the dominant role of interfacial electrostatic interactions. Electrochemical analysis shows that DG favors electronic transport at the expense of ionic accumulation, whereas NZ maintains capacitive behavior. The nanocomposites exhibit good biocompatibility, with improved SH‐SY5Y cell viability at low DG loading. These results provide design guidelines for independently tuning electrical, electrochemical, and mechanical properties in conductive polymer nanocomposites.